Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.69 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DHPS | P49366 | 1/20 | 0.39 |
| ▸ | MPL | P40238 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669913 | 0.82 | SMN1; SMN2 (0.59) | HSP90AA1MAPK1ADORA2ASMN1; SMN2ADORA1 | |
| SCHEMBL29803060 | 0.82 | SMN1; SMN2 (0.59) | HSP90AA1MAPK1ADORA2ASMN1; SMN2ADORA1 | |
| SCHEMBL17156503 | 0.82 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1MAPK1ADORA2AADORA1 | |
| SCHEMBL4086070 | 0.81 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MAPK1ADORA2ASMN1; SMN2 | |
| SCHEMBL9565604 | 0.77 | KDM4E (0.53) | HSP90AA1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4093530 | 0.76 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL1704219 | 0.74 | KDM4E (0.69) | HSP90AA1HSP90AB1MAPK1ADORA2ASMN1; SMN2 | |
| SCHEMBL23405305 | 0.74 | MAPK1 (0.41) | HSP90AA1MAPK1ADORA2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6310578 | 0.73 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1ADORA2ASMN1; SMN2ADORA1 | |
| SCHEMBL27826457 | 0.73 | MPL (0.45) | HSP90AA1MAPK1ADORA2ASMN1; SMN2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919339-B2 | ABCA-1 elevating compounds | CV THEAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020128266-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128266-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | HSP90AA1 1676/4885HSP90AB1 1191/4885MAPK1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.